This company has been acquired
AVEO Pharmaceuticals Crecimiento futuro
Future controles de criterios 5/6
Información clave
123.0%
Tasa de crecimiento de los beneficios
122.8%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 25.1% |
| Tasa de crecimiento de los ingresos | 36.2% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
AVEO Oncology shares jumped on acqusition by LG Chem for $15.00 per share in cash
Oct 18Here's Why AVEO Pharmaceuticals (NASDAQ:AVEO) Can Manage Its Debt Despite Losing Money
Oct 04
A Current Assessment On AVEO Pharmaceuticals
Aug 15Rock star Growth Puts AVEO Pharmaceuticals (NASDAQ:AVEO) In A Position To Use Debt
Jun 21AVEO Pharmaceuticals Is Primed For A Breakout
May 24Here's What Analysts Are Forecasting For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) After Its Annual Results
Mar 17AVEO Pharmaceuticals: Finally Ready To Reboot
Mar 09AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Mar 03AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 23AVEO Pharmaceuticals: Sticking To The Plan
Oct 29AVEO Pharmaceuticals: Making Its Mark In Cancer Treatment
Jul 24AVEO Oncology: Time To Be Patient
Jun 07AVEO outlines 2021 outlook; initiates Phase 1 trial for cancer complication
Jan 07AVEO Oncology: Managing A Position Ahead Of Tivozanib's PDUFA
Dec 27Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2024 | 214 | 48 | N/A | N/A | 1 |
| 12/31/2023 | 162 | 12 | N/A | N/A | 1 |
| 12/31/2022 | 110 | -24 | N/A | N/A | 1 |
| 9/30/2022 | 94 | -29 | -23 | -23 | N/A |
| 6/30/2022 | 79 | -36 | -31 | -31 | N/A |
| 3/31/2022 | 61 | -41 | -47 | -47 | N/A |
| 12/31/2021 | 42 | -53 | -57 | -57 | N/A |
| 9/30/2021 | 26 | -58 | -58 | -58 | N/A |
| 6/30/2021 | 14 | -56 | -56 | -56 | N/A |
| 3/31/2021 | 7 | -49 | -45 | -45 | N/A |
| 12/31/2020 | 6 | -36 | -38 | -38 | N/A |
| 9/30/2020 | 6 | -29 | -33 | -32 | N/A |
| 6/30/2020 | 28 | -4 | -8 | -8 | N/A |
| 3/31/2020 | 28 | 0 | -6 | -6 | N/A |
| 12/31/2019 | 29 | 9 | -3 | -3 | N/A |
| 9/30/2019 | 30 | 36 | -2 | -2 | N/A |
| 6/30/2019 | 6 | -3 | -24 | -24 | N/A |
| 3/31/2019 | 6 | 4 | -27 | -27 | N/A |
| 12/31/2018 | 5 | -5 | -25 | -25 | N/A |
| 9/30/2018 | 4 | -24 | -22 | -22 | N/A |
| 6/30/2018 | 6 | -28 | -22 | -22 | N/A |
| 3/31/2018 | 6 | -65 | -20 | -20 | N/A |
| 12/31/2017 | 8 | -65 | -19 | -19 | N/A |
| 9/30/2017 | 8 | -74 | -23 | -23 | N/A |
| 6/30/2017 | 4 | -53 | -29 | -29 | N/A |
| 3/31/2017 | 4 | -28 | -26 | -26 | N/A |
| 12/31/2016 | 3 | -27 | -31 | -31 | N/A |
| 9/30/2016 | 6 | -28 | -24 | -24 | N/A |
| 6/30/2016 | 20 | -15 | N/A | -6 | N/A |
| 3/31/2016 | 20 | -12 | N/A | -13 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: AVEO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Beneficios vs. Mercado: AVEO is forecast to become profitable over the next 3 years, which is considered above average market growth.
Beneficios de alto crecimiento: AVEO is expected to become profitable in the next 3 years.
Ingresos vs. Mercado: AVEO's revenue (36.2% per year) is forecast to grow faster than the US market (6.9% per year).
Ingresos de alto crecimiento: AVEO's revenue (36.2% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if AVEO's Return on Equity is forecast to be high in 3 years time